ATE432933T1 - Flavopereirinderivate zur krebstherapie - Google Patents

Flavopereirinderivate zur krebstherapie

Info

Publication number
ATE432933T1
ATE432933T1 AT04745116T AT04745116T ATE432933T1 AT E432933 T1 ATE432933 T1 AT E432933T1 AT 04745116 T AT04745116 T AT 04745116T AT 04745116 T AT04745116 T AT 04745116T AT E432933 T1 ATE432933 T1 AT E432933T1
Authority
AT
Austria
Prior art keywords
derivatives
flavoperei
flavopereirine
cancer therapy
inhibition
Prior art date
Application number
AT04745116T
Other languages
English (en)
Inventor
V Seshagiri
Rama Mukherjee
Anand C Burman
Mukund K Gurjar
J S Yadav
Manu Jaggi
Anu T Singh
Sanjay K Srivastava
P Jaisankar
Bikash Pal
Asish K Banerjee
Radhika D Wakharkar
Original Assignee
Dabur Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Pharma Ltd filed Critical Dabur Pharma Ltd
Application granted granted Critical
Publication of ATE432933T1 publication Critical patent/ATE432933T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04745116T 2004-06-11 2004-06-11 Flavopereirinderivate zur krebstherapie ATE432933T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000167 WO2005121143A1 (en) 2004-06-11 2004-06-11 Flavopereirine derivatives for cancer therapy

Publications (1)

Publication Number Publication Date
ATE432933T1 true ATE432933T1 (de) 2009-06-15

Family

ID=34957880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04745116T ATE432933T1 (de) 2004-06-11 2004-06-11 Flavopereirinderivate zur krebstherapie

Country Status (5)

Country Link
US (1) US20100256177A1 (de)
EP (1) EP1758904B1 (de)
AT (1) ATE432933T1 (de)
DE (1) DE602004021439D1 (de)
WO (1) WO2005121143A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532664A1 (de) * 2011-06-09 2012-12-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substituierte Indolo[2,3-a]chinolizine zur Behandlung von Krebs
EP3773582B1 (de) 2018-03-31 2023-10-25 Molecular International Research, Inc. Selektives antikrebsmittel zur vorbeugung und behandlung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3172570D1 (en) * 1981-03-11 1985-11-14 Mirko Beljanski Serpentine, alstonine and sempervirine drugs for the specific inhibition of tumurous and cancerous cells
FR2694693B1 (fr) * 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.

Also Published As

Publication number Publication date
US20100256177A1 (en) 2010-10-07
WO2005121143A1 (en) 2005-12-22
EP1758904A1 (de) 2007-03-07
EP1758904B1 (de) 2009-06-03
DE602004021439D1 (de) 2009-07-16

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
SI1853602T1 (sl) Kemične spojine
GB2430935A (en) Tetrapeptide analogs
PL1853588T3 (pl) Związki chemiczne
SG170809A1 (en) Diarylthiohydantoin compounds
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200802213A1 (ru) Способы лечения заболеваний крови
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
TW200626068A (en) Active compounds for seed treatment
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
MY148617A (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE432933T1 (de) Flavopereirinderivate zur krebstherapie
MX2007001954A (es) Heterociclicos fusionados seleccionados y sus usos.
ATE392408T1 (de) Cyclopentenon-derivate für krebs-therapie
NO20064185L (no) Pyrazolin derivater nyttige for bahandling av kreft
DK1687301T3 (da) Thiaepothilone til behandling af kræftsygdomme
TW200621270A (en) Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold
NZ597948A (en) Combinations for the treatment of diseases involving cell proliferation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties